# Single-ascending-dose Study of the Safety and Immunogenicity of NasoVAX

> **NCT03232567** · PHASE2 · COMPLETED · sponsor: **Altimmune, Inc.** · enrollment: 60 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** NasoVAX

## Key facts

- **NCT ID:** NCT03232567
- **Lead sponsor:** Altimmune, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-18
- **Primary completion:** 2018-03-07
- **Final completion:** 2018-06-15
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2024-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03232567

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03232567, "Single-ascending-dose Study of the Safety and Immunogenicity of NasoVAX". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03232567. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*